Loading...
XSHE
300039
Market cap676mUSD
Jul 10, Last price  
4.49CNY
1D
2.28%
1Q
-25.04%
Jan 2017
-42.94%
IPO
1.74%
Name

Shanghai Kaibao Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300039 chart
P/E
16.86
P/S
4.07
EPS
0.27
Div Yield, %
2.96%
Shrs. gr., 5y
Rev. gr., 5y
0.93%
Revenues
1.15b
-21.76%
387,385,788458,887,998603,414,409819,968,6291,089,926,3261,323,215,4341,620,843,2621,395,788,5751,497,151,2171,569,916,0321,500,676,4541,419,026,169908,008,8611,100,578,3911,100,578,3911,118,850,5251,118,850,5241,594,051,4701,473,319,0461,152,662,433
Net income
279m
-25.83%
57,654,63968,668,694123,700,058167,563,306242,191,974318,815,443351,921,218281,648,524282,606,844272,304,673226,812,440250,986,455106,122,752140,113,625140,113,630190,804,507190,804,513327,870,834375,578,027278,584,264
CFO
231m
-17.28%
19,697,43723,270,70818,695,18252,738,05619,787,85598,307,480243,323,767270,234,671282,378,515327,081,937314,879,061245,758,441262,361,430334,085,296250,649,879126,078,156376,418,583382,664,971278,950,298230,741,218
Dividend
Nov 27, 20250.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Kaibao Pharmaceutical CO.,Ltd specializes in the research, development, manufacturing, and sale of modern Traditional Chinese Medicines, primarily operating within China. Its diverse product lineup features several key pharmaceutical solutions. These include: Tanreqing injection, which is extensively utilized for addressing conditions like pneumonia, acute and chronic bronchitis, and upper respiratory tract infections. Tanreqing capsules, formulated to reduce internal heat, detoxify the system, and clear phlegm. Tiopronin for injection, designed to enhance liver function for various acute and chronic hepatitis patients. Tiopronin enteric-coated tablets, prescribed as a supplementary therapy for managing chronic hepatitis. Xiongdan dropping pills, known for their efficacy in alleviating heat, calming the liver, and promoting improved vision. Established in 2000, the company's operations are based in Shanghai, China.
IPO date
Jan 08, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT